Group purchasing organization Vizient reported a 610 percent boost in demand from June 16-19, the period just after preliminary study results suggested dexamethasone — an inexpensive steroid often used to treat asthma, arthritis and some cancers — could improve mortality rates among the sickest COVID-19 patients.
The rate at which drugmakers could fill dexamethasone orders and send them to hospitals dropped from 97 to 54 percent by June 19, according to Vizient.
More articles on pharmacy:
Ramping up US drug production: 3 obstacles to consider
APhA launches task force, #PharmacistsFightingRacism campaign
Sanofi expedites its vaccine timeline, strikes $2.3B deal with Translate Bio
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.